Vol. 11, Issue 5, Part B (2025)

Abstract
Human skin allografts (HSAs) have emerged as a promising treatment for severe burns, yet their clinical and economic benefits compared to standard therapies remain incompletely characterized. This systematic review analysed 30 studies (2010-2023) from PubMed/Web of Science, including randomized trials, meta-analyses and observational studies. We evaluated clinical outcomes (healing time, infection rates, mortality) and economic impacts (cost savings, resource utilization) using AMSTAR 2 for quality assessment. HSAs demonstrated superior outcomes versus alternatives: 32-45% lower infection rates (OR 0.62, p<0.05), 3.2-5.2-day faster epithelialization and 20-35% mortality reduction in high-risk patients. Economic analyses revealed 7,800−14,000 per-case savings through reduced surgeries (30% fewer) and shorter hospital stays (3.5-4.5 days). Specialized applications showed particular benefit, with 50% less scarring in paediatric burns and superior aesthetic results in facial reconstruction. HSAs offer clinically and economically superior outcomes for burn management, especially in extensive burns and anatomically sensitive areas. These findings support broader HSA adoption in burn protocols, though further research should optimize preservation techniques and evaluate implementation in resource-limited settings.